Centre for Cancer Immunology, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, United Kingdom.
Institute for Life Sciences, University of Southampton, Southampton, United Kingdom.
Cancer Immunol Res. 2019 Jul;7(7):1202-1213. doi: 10.1158/2326-6066.CIR-18-0498. Epub 2019 May 31.
Presence of tumor-infiltrating lymphocytes (TIL) predicts survival in many cancer types. In HPV-driven cancers, cervical and oropharyngeal squamous cell carcinomas (CSCC and OPSCC, respectively), numbers of infiltrating T cells, particularly CD8 T cells, and presentation of HPV E6/E7 epitopes are associated with improved prognosis. Endoplasmic reticulum aminopeptidase 1 (ERAP1) regulates the presented peptide repertoire, trimming peptide precursors prior to MHC I loading. ERAP1 is polymorphic, and allotypic variation of ERAP1 enzyme activity has an impact on the presented peptide repertoire. Individual SNPs are associated with incidence and outcome in a number of diseases, including CSCC. Here, we highlight the requirement for ERAP1 in the generation of HPV E6/E7 epitopes and show that the functional activity of ERAP1 allotype combinations identified in OPSCC correlate with tumor-infiltrating CD8 T-cell (CD8)/TIL (CD8/TIL) status of the tumor. Functional analyses revealed that ERAP1 allotype combinations associated with CD8/TIL tumors have a reduced capacity to generate both a model antigen SIINFEHL and the HPV-16 E7 epitope LLMGTLGIV from N-terminally extended precursor peptides. In contrast, ERAP1 allotypes from CD8/TIL tumors generated the epitopes efficiently. These data reveal that ERAP1 function correlates with CD8/TIL numbers and, by implication, prognosis, suggesting that the presentation of HPV-16 epitopes at the cell surface, resulting in an anti-HPV T-cell response, may depend on the ERAP1 allotype combinations expressed within an individual.
肿瘤浸润淋巴细胞 (TIL) 的存在可预测多种癌症类型的生存率。在 HPV 驱动的癌症中,宫颈和口咽鳞状细胞癌(分别为 CSCC 和 OPSCC)中,浸润 T 细胞的数量,特别是 CD8 T 细胞,以及 HPV E6/E7 表位的呈现与改善的预后相关。内质网氨肽酶 1 (ERAP1) 调节呈递的肽库,在 MHC I 加载之前修剪肽前体。ERAP1 是多态的,ERAP1 酶活性的同种型变异对呈递的肽库有影响。个体 SNP 与包括 CSCC 在内的许多疾病的发病率和结果相关。在这里,我们强调了 ERAP1 在 HPV E6/E7 表位产生中的必要性,并表明在 OPSCC 中鉴定的 ERAP1 同种型组合的功能活性与肿瘤浸润的 CD8 T 细胞 (CD8)/TIL (CD8/TIL) 状态相关。功能分析表明,与 CD8/TIL 肿瘤相关的 ERAP1 同种型组合从 N 端扩展的前体肽生成模型抗原 SIINFEHL 和 HPV-16 E7 表位 LLMGTLGIV 的能力降低。相比之下,来自 CD8/TIL 肿瘤的 ERAP1 同种型有效地生成了这些表位。这些数据表明 ERAP1 功能与 CD8/TIL 数量相关,因此与预后相关,这表明 HPV-16 表位在细胞表面的呈现,导致针对 HPV 的 T 细胞反应,可能取决于个体中表达的 ERAP1 同种型组合。